Association between proton pump inhibitors after percutaneous coronary intervention and risk of gastric cancer.
Andrew Kei-Yan NgPauline Yeung NgApril IpKa-Shing CheungChung-Wah SiuPublished in: BMJ open gastroenterology (2021)
Chronic use of PPI was significantly associated with increased risk of gastric cancer and death from gastric cancer in patients for whom it was prescribed as prophylaxis. Physicians should judiciously assess the relevant risks and benefits of chronic PPI use before prescription.
Keyphrases
- percutaneous coronary intervention
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- primary care
- acute myocardial infarction
- protein protein
- prognostic factors
- peritoneal dialysis
- coronary artery bypass grafting
- st elevation myocardial infarction
- atrial fibrillation
- antiplatelet therapy
- human health
- risk assessment
- patient reported outcomes
- left ventricular
- coronary artery bypass